Title: ASTIN: a Bayesian adaptive dose-response trial in acute stroke. Author: Grieve AP, Krams M. Journal: Clin Trials; 2005; 2(4):340-51; discussion 352-8, 364-78. PubMed ID: 16281432. Abstract: Understanding the dose-response is critical for successful drug development. We describe an adaptive design to efficiently learn about the dose-response and the ED95. A dynamic termination rule allows for early discontinuation either for efficacy or futility. The design was deployed in ASTIN, a phase II proof-of-concept trial of the neuroprotectant, neutrophil inhibitory factor (NIF), in acute stroke. We discuss the learning from this trial.[Abstract] [Full Text] [Related] [New Search]
